Format
Sort by

Send to

Choose Destination

Search results

Items: 1 to 20 of 487

1.

Retrospective analysis of molecular scores for the prediction of distant recurrence according to baseline risk factors.

Sestak I, Dowsett M, Ferree S, Baehner FL, Cuzick J.

Breast Cancer Res Treat. 2016 Jul 22. [Epub ahead of print]

PMID:
27447876
2.

Safety Profile of the 9-Valent HPV Vaccine: A Combined Analysis of 7 Phase III Clinical Trials.

Moreira ED Jr, Block SL, Ferris D, Giuliano AR, Iversen OE, Joura EA, Kosalaraksa P, Schilling A, Van Damme P, Bornstein J, Bosch FX, Pils S, Cuzick J, Garland SM, Huh W, Kjaer SK, Qi H, Hyatt D, Martin J, Moeller E, Ritter M, Baudin M, Luxembourg A.

Pediatrics. 2016 Jul 15. pii: e20154387. [Epub ahead of print]

PMID:
27422279
3.

Comparison of EndoPredict and EPclin With Oncotype DX Recurrence Score for Prediction of Risk of Distant Recurrence After Endocrine Therapy.

Buus R, Sestak I, Kronenwett R, Denkert C, Dubsky P, Krappmann K, Scheer M, Petry C, Cuzick J, Dowsett M.

J Natl Cancer Inst. 2016 Jul 10;108(11). pii: djw149. doi: 10.1093/jnci/djw149. Print 2016 Nov.

4.

Relationship of ZNF423 and CTSO with breast cancer risk in two randomised tamoxifen prevention trials.

Brentnall AR, Cuzick J, Byers H, Segal C, Reuter C, Detre S, Sestak I, Howell A, Powles TJ, Newman WG, Dowsett M.

Breast Cancer Res Treat. 2016 Jul 11. [Epub ahead of print]

PMID:
27400912
5.

Clinician-Reported Barriers to Implementing Breast Cancer Chemoprevention in the UK: A Qualitative Investigation.

Smith SG, Side L, Meisel SF, Horne R, Cuzick J, Wardle J.

Public Health Genomics. 2016 Jul 12. [Epub ahead of print]

6.

Performance of a cartridge based assay for the detection of clinically significant HPV infection - lessons from VALGENT (Validation of HPV Genotyping Tests).

Cuschieri K, Geraets D, Cuzick J, Cadman L, Moore C, Vanden Broeck D, Padalko E, Quint W, Arbyn M.

J Clin Microbiol. 2016 Jul 6. pii: JCM.00897-16. [Epub ahead of print]

PMID:
27385707
7.

Ovarian cancer screening: UKCTOCS trial.

Sasieni PD, Duffy SW, Cuzick J.

Lancet. 2016 Jun 25;387(10038):2602. doi: 10.1016/S0140-6736(16)30847-9. No abstract available.

PMID:
27353820
8.

Cross Stratification and Differential Risk by Breast Cancer Index and Recurrence Score in women with hormone receptor positive lymph-node negative early stage breast cancer.

Sestak I, Zhang Y, Schroeder BE, Schnabel CA, Dowsett M, Cuzick J, Sgroi D.

Clin Cancer Res. 2016 Jun 1. pii: clincanres.0155.2016. [Epub ahead of print]

PMID:
27252417
9.

Impact of Screening on Breast Cancer Mortality-Response.

Massat NJ, Dibden A, Parmar D, Cuzick J, Sasieni PD, Duffy SW.

Cancer Epidemiol Biomarkers Prev. 2016 May;25(5):873. doi: 10.1158/1055-9965.EPI-16-0170. No abstract available.

PMID:
27197146
10.

Validation of a contemporary prostate cancer grading system using prostate cancer death as outcome.

Berney DM, Beltran L, Fisher G, North BV, Greenberg D, Møller H, Soosay G, Scardino P, Cuzick J.

Br J Cancer. 2016 May 10;114(10):1078-83. doi: 10.1038/bjc.2016.86. Epub 2016 Apr 21.

PMID:
27100731
11.

Breast cancer risk feedback to women in the UK NHS breast screening population.

Evans DG, Donnelly LS, Harkness EF, Astley SM, Stavrinos P, Dawe S, Watterson D, Fox L, Sergeant JC, Ingham S, Harvie MN, Wilson M, Beetles U, Buchan I, Brentnall AR, French DP, Cuzick J, Howell A.

Br J Cancer. 2016 Apr 26;114(9):1045-52. doi: 10.1038/bjc.2016.56. Epub 2016 Mar 29.

PMID:
27022688
12.

iPrevent®: a tailored, web-based, decision support tool for breast cancer risk assessment and management.

Collins IM, Bickerstaffe A, Ranaweera T, Maddumarachchi S, Keogh L, Emery J, Mann GB, Butow P, Weideman P, Steel E, Trainer A, Bressel M, Hopper JL, Cuzick J, Antoniou AC, Phillips KA.

Breast Cancer Res Treat. 2016 Feb;156(1):171-82. doi: 10.1007/s10549-016-3726-y. Epub 2016 Feb 24.

13.

Differing Perspectives on Breast Cancer Chemoprevention.

Cuzick J, Wickerham L, Powles T.

JAMA Oncol. 2016 Feb;2(2):276-7. doi: 10.1001/jamaoncol.2015.4406. No abstract available.

PMID:
26869000
14.

Observation versus late reintroduction of letrozole as adjuvant endocrine therapy for hormone receptor-positive breast cancer (ANZ0501 LATER): an open-label randomised, controlled trial.

Zdenkowski N, Forbes JF, Boyle FM, Kannourakis G, Gill PG, Bayliss E, Saunders C, Della-Fiorentina S, Kling N, Campbell I, Mann GB, Coates AS, Gebski V, Davies L, Thornton R, Reaby L, Cuzick J, Green M; Australia and New Zealand Breast Cancer Trials Group.

Ann Oncol. 2016 May;27(5):806-12. doi: 10.1093/annonc/mdw055. Epub 2016 Feb 9.

PMID:
26861603
15.

Incidence of multiple myeloma in Great Britain, Sweden, and Malmö, Sweden: the impact of differences in case ascertainment on observed incidence trends.

Vélez R, Turesson I, Landgren O, Kristinsson SY, Cuzick J.

BMJ Open. 2016 Jan 21;6(1):e009584. doi: 10.1136/bmjopen-2015-009584.

16.

Validation of a DNA methylation HPV triage classifier in a screening sample.

Lorincz AT, Brentnall AR, Scibior-Bentkowska D, Reuter C, Banwait R, Cadman L, Austin J, Cuzick J, Vasiljević N.

Int J Cancer. 2016 Jun 1;138(11):2745-51. doi: 10.1002/ijc.30008. Epub 2016 Feb 8.

17.

PIK3CA Mutation, Aspirin Use after Diagnosis and Survival of Colorectal Cancer. A Systematic Review and Meta-analysis of Epidemiological Studies.

Paleari L, Puntoni M, Clavarezza M, DeCensi M, Cuzick J, DeCensi A.

Clin Oncol (R Coll Radiol). 2016 May;28(5):317-26. doi: 10.1016/j.clon.2015.11.008. Epub 2015 Dec 17.

PMID:
26712086
18.

Anastrozole versus tamoxifen for the prevention of locoregional and contralateral breast cancer in postmenopausal women with locally excised ductal carcinoma in situ (IBIS-II DCIS): a double-blind, randomised controlled trial.

Forbes JF, Sestak I, Howell A, Bonanni B, Bundred N, Levy C, von Minckwitz G, Eiermann W, Neven P, Stierer M, Holcombe C, Coleman RE, Jones L, Ellis I, Cuzick J; IBIS-II investigators.

Lancet. 2016 Feb 27;387(10021):866-73. doi: 10.1016/S0140-6736(15)01129-0. Epub 2015 Dec 11.

19.

Factors affecting uptake and adherence to breast cancer chemoprevention: a systematic review and meta-analysis.

Smith SG, Sestak I, Forster A, Partridge A, Side L, Wolf MS, Horne R, Wardle J, Cuzick J.

Ann Oncol. 2016 Apr;27(4):575-90. doi: 10.1093/annonc/mdv590. Epub 2015 Dec 8. Review.

20.

Impact of Screening on Breast Cancer Mortality: The UK Program 20 Years On.

Massat NJ, Dibden A, Parmar D, Cuzick J, Sasieni PD, Duffy SW.

Cancer Epidemiol Biomarkers Prev. 2016 Mar;25(3):455-62. doi: 10.1158/1055-9965.EPI-15-0803. Epub 2015 Dec 8.

PMID:
26646362
Items per page

Supplemental Content

Loading ...
Write to the Help Desk